Advertisement

PharmacoEconomics

, Volume 36, Issue 11, pp 1355–1365 | Cite as

Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients

  • Kristina R. Dahlstrom
  • Shuangshuang Fu
  • Wenyaw Chan
  • Zeena Shelal
  • Lois M. Ramondetta
  • David R. Lairson
Original Research Article

Abstract

Introduction

Genital warts are caused by infection with human papillomavirus (HPV) and are associated with significant morbidity. Primary prevention of genital warts is possible through HPV vaccination, but vaccination rates remain low in the USA. When deciding to implement HPV vaccination programs, public health officials and policy makers rely on cost-effectiveness studies that accurately reflect costs associated with morbidity and mortality. However, previous information on the cost of treating genital warts was outdated.

Objectives

We estimated the mean direct medical care costs associated with genital warts in the USA.

Methods

This was a retrospective case–control study of patients diagnosed with genital warts and matched controls. We used commercial healthcare claims data from 2011 through 2014 to estimate total 1- and 2-year costs from date of diagnosis. We used a generalized linear model to identify factors associated with monthly costs.

Results

We identified 34,686 eligible cases of genital warts during the period 2011–2014. The first 2-year mean direct medical cost differences between cases and controls were US$6737 for the USA. Costs were significantly higher in the first 3 months following diagnosis and were higher among older individuals, women, those with co-morbidities or psychiatric illnesses, and those located in the south and southwest USA.

Conclusions

The mean direct cost of treating genital warts is approximately US$6700 in the first 2 years after diagnosis in the USA. These data can assist policy makers in decisions with respect to allocation of resources to implement HPV vaccine programs.

Notes

Acknowledgements

Editorial assistance was provided by Sunita Patterson of MD Anderson Cancer Center’s Department of Scientific Publications.

Author Contributions

Study concept and design: Lairson and Wen; data analysis: Lairson, Wen, and Fu; all authors participated in the interpretation of data and drafting, critical review, and final approval of the manuscript.

Compliance with Ethical Standards

Funding

This study was supported by generous philanthropic contributions, including a contribution from the Lyda Hill Foundation to The University of Texas MD Anderson Cancer Center’s Moon Shots Program, and was accomplished within the Oropharynx Program at The University of Texas MD Anderson Cancer Center and funded in part through the Stiefel Oropharyngeal Research Fund.

Conflict of Interest

Kristina R. Dahlstrom, Shuangshuang Fu, Wenyaw Chan, Zeena Shelal, Lois M. Ramondetta, and David R. Lairson have no conflict of interests to disclose.

Ethical Approval

For this type of study formal consent is not required.

Data Availability Statement

The MarketScan claims data are available from Truven Health Analytics, now part of IBM Watson Health, with access fees subject to the level of research funding. Contact Dr Lairson for software code requests.

Supplementary material

40273_2018_691_MOESM1_ESM.pdf (295 kb)
Supplementary material 1 (PDF 294 kb)

References

  1. 1.
    Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118:831–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999–2004. Sex Transm Dis. 2008;35:357–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2016. Atlanta: US Department of Health and Human Services; 2017.Google Scholar
  6. 6.
    Camenga DR, Dunne EF, Desai MM, et al. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013;40:534–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Raymakers AJ, Sadatsafavi M, Marra F, Marra CA. Economic and humanistic burden of external genital warts. Pharmacoeconomics. 2012;30:1–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009;85:111–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1–137.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.PubMedGoogle Scholar
  13. 13.
    Walker TY, Elam-Evans LD, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:874–82.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168:76–82.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Brisson M, Laprise JF, Chesson HW, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2015;108:djv282.  https://doi.org/10.1093/jnci/djv282.CrossRefPubMedGoogle Scholar
  17. 17.
    Pink J, Parker B, Petrou S. Cost effectiveness of HPV vaccination: a systematic review of modelling approaches. Pharmacoeconomics. 2016;34:847–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Lairson DR, Fu S, Chan W, Xu L, Shelal Z, Ramondetta L. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017;145:108–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Jacobson JJ, Epstein JB, Eichmiller FC, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid. Head Neck Oncol. 2012;4:15 (3284-4-15).CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yabroff KR, Warren JL, Schrag D, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009;47:S56–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Mattingly TJ, Mullins CD, Onukwugha E. Publication of cost-of-illness studies: does methodological complexity matter? Pharmacoeconomics. 2016;34:1067–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34:43–58.CrossRefPubMedGoogle Scholar
  23. 23.
    Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77:251–77.PubMedGoogle Scholar
  24. 24.
    Rubin DB. Bias reduction using Mahalanobis-metric matching. Biometrics. 1980;36:293–8.CrossRefGoogle Scholar
  25. 25.
    Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33:1057–69.CrossRefPubMedGoogle Scholar
  26. 26.
    D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49:1429–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Ashcraft ML, Fries BE, Nerenz DR, et al. A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care. 1989;27:543–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Bureau of Labor Statistics. Consumer Price Index-Medical Care. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed 10 Oct 2017.
  29. 29.
    Glick H, Doshi J, Sonnad S, Polsky D. Analyzing cost. In: Anonymous economic evaluation in clinical trials. New York: Oxford University Press; 2014. pp. 96.Google Scholar
  30. 30.
    Akaike H. Likelihood of a model and information criteria. J Econom. 1981;16:3–14.CrossRefGoogle Scholar
  31. 31.
    Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76 (2334-8-76).CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gianino MM, Delmonte S, Lovato E, et al. A retrospective analysis of the costs and management of genital warts in Italy. BMC Infect Dis. 2013;13:470 (2334-13-470).CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ostensson E, Froberg M, Leval A, et al. Cost of preventing, managing, and treating human papillomavirus (HPV)-related diseases in Sweden before the introduction of quadrivalent HPV vaccination. PLoS One. 2015;10:e0139062.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ginindza TG, Sartorius B, Dlamini X, Ostensson E. Cost analysis of human papillomavirus-related cervical diseases and genital warts in Swaziland. PLoS One. 2017;12:e0177762.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Anderson GF, Reinhardt UE, Hussey PS, Petrosyan V. It’s the prices, stupid: why the United States is so different from other countries. Health Aff (Millwood). 2003;22:89–105.CrossRefPubMedGoogle Scholar
  36. 36.
    Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198:500.e1–7.CrossRefGoogle Scholar
  37. 37.
    Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397–403.CrossRefPubMedGoogle Scholar
  39. 39.
    Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009;25:2343–51.CrossRefPubMedGoogle Scholar
  40. 40.
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.CrossRefPubMedGoogle Scholar
  41. 41.
    FUTURE I/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.CrossRefGoogle Scholar
  42. 42.
    Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa). 2009;2:868–78.CrossRefGoogle Scholar
  43. 43.
    Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325–39.CrossRefPubMedGoogle Scholar
  44. 44.
    Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39–44.CrossRefPubMedGoogle Scholar
  45. 45.
    Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.CrossRefPubMedGoogle Scholar
  46. 46.
    Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103:1428–35.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 2016;16:52 (016-1347-z).CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women. Sex Transm Dis. 2016;43:238–42.CrossRefPubMedGoogle Scholar
  49. 49.
    Marra C, Ogilvie G, Gastonguay L, Colley L, Taylor D, Marra F. Patients with genital warts have a decreased quality of life. Sex Transm Dis. 2009;36:258–60.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Kristina R. Dahlstrom
    • 1
  • Shuangshuang Fu
    • 1
    • 2
  • Wenyaw Chan
    • 3
  • Zeena Shelal
    • 4
  • Lois M. Ramondetta
    • 4
  • David R. Lairson
    • 5
  1. 1.Department of Head and Neck Surgery, Division of SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Epidemiology, Human Genetics & Environmental Sciences, School of Public HealthThe University of Texas Health Science Center at HoustonHoustonUSA
  3. 3.Department of Biostatistics, School of Public HealthThe University of Texas Health Science Center at HoustonHoustonUSA
  4. 4.Department of Gynecologic Oncology and Reproductive MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Department of Management, Policy, and Community Health, School of Public HealthThe University of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations